Recordati SpA (Recordati SpA) Days Payable : 137.89 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Days Payable?

Recordati SpA's average Accounts Payable for the three months ended in Dec. 2023 was $279 Mil. Recordati SpA's Cost of Goods Sold for the three months ended in Dec. 2023 was $185 Mil. Hence, Recordati SpA's Days Payable for the three months ended in Dec. 2023 was 137.89.

The historical rank and industry rank for Recordati SpA's Days Payable or its related term are showing as below:

RCDTF' s Days Payable Range Over the Past 10 Years
Min: 116.91 Med: 130.97 Max: 142.23
Current: 136.83

During the past 13 years, Recordati SpA's highest Days Payable was 142.23. The lowest was 116.91. And the median was 130.97.

RCDTF's Days Payable is ranked better than
72.26% of 977 companies
in the Drug Manufacturers industry
Industry Median: 87.01 vs RCDTF: 136.83

Recordati SpA's Days Payable increased from Dec. 2022 (136.30) to Dec. 2023 (137.89). It may suggest that Recordati SpA delayed paying its suppliers.

Recordati SpA Days Payable Historical Data

The historical data trend for Recordati SpA's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Days Payable Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

143.88

131.15

136.60

133.47

133.41

Recordati SpA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															136.30	130.84	151.39	128.95	137.89

Competitive Comparison of Recordati SpA's Days Payable

For the Drug Manufacturers - General subindustry, Recordati SpA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recordati SpA's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Days Payable distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Days Payable falls into.

Recordati SpA Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Recordati SpA's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (238.033	+	287.872)	/	2 )	/	719.419	*	365
=	262.9525					/	719.419	*	365
=	133.41

Recordati SpA's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (269.825	+	287.872)	/	2 )	/	184.528	*	365 / 4
=	278.8485					/	184.528	*	365 / 4
=	137.89

Recordati SpA Days Payable Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (Recordati SpA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing's Disease Published in Lancet Diabetes & Endocrinology

By Business Wire Business Wire • 07-28-2020

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa� (Osilodrostat) in Patients With Cushing's Disease

By Business Wire Business Wire • 03-29-2022

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire • 03-09-2020

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)

By Business Wire Business Wire • 06-02-2020

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy� (ARS-1; epinephrine nasal spray)

By PRNewswire PRNewswire • 09-22-2020

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa� (Osilodrostat) in Patients With Cushing's Disease in the European Journal of Endocrinology

By Business Wire Business Wire • 08-31-2022

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany

By Business Wire Business Wire • 07-16-2020

Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing's Disease

By Business Wire Business Wire • 06-17-2020